Extranodal marginal zone lymphoma as the presenting feature of paediatric Sjögren syndrome.

Pediatric Blood & CancerEarly View e30476 LETTER TO THE EDITOR Extranodal marginal zone lymphoma as the presenting feature of paediatric Sjögren syndrome Sarah Long, Sarah Long Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorJosephine Vila, Josephine Vila Department of Rheumatology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorDavid Meikle, David Meikle Ear, Nose and Throat Service, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorWan-Fai Ng, Wan-Fai Ng Department of Rheumatology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UKSearch for more papers by this authorAlexandr Svec, Alexandr Svec Department of Cellular Pathology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UKSearch for more papers by this authorDespina Televantou, Despina Televantou Department of Cellular Pathology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorKatrina M. Wood, Katrina M. Wood Department of Cellular Pathology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorChris M. Bacon, Chris M. Bacon Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK Department of Cellular Pathology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorSimon Bomken, Corresponding Author Simon Bomken [email protected] orcid.org/0000-0001-9163-5738 Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK Correspondence Simon Bomken, Level 6, Herschel Bldg, Brewery Lane, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. Email: [email protected]Search for more papers by this author Sarah Long, Sarah Long Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorJosephine Vila, Josephine Vila Department of Rheumatology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorDavid Meikle, David Meikle Ear, Nose and Throat Service, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorWan-Fai Ng, Wan-Fai Ng Department of Rheumatology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UKSearch for more papers by this authorAlexandr Svec, Alexandr Svec Department of Cellular Pathology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UKSearch for more papers by this authorDespina Televantou, Despina Televantou Department of Cellular Pathology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorKatrina M. Wood, Katrina M. Wood Department of Cellular Pathology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorChris M. Bacon, Chris M. Bacon Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK Department of Cellular Pathology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UKSearch for more papers by this authorSimon Bomken, Corresponding Author Simon Bomken [email protected] orcid.org/0000-0001-9163-5738 Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK Correspondence Simon Bomken, Level 6, Herschel Bldg, Brewery Lane, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. Email: [email protected]Search for more papers by this author First published: 03 June 2023 https://doi.org/10.1002/pbc.30476Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36(7): 1720- 1748. 2Laurent C, Cook JR, Yoshino T, Quintanilla-Martinez L, Jaffe ES. Follicular lymphoma and marginal zone lymphoma: how many diseases? Virchows Arch. 2023; 482(1): 149- 162. 3Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 1: 307- 313. 4Makarova O, Oschlies I, Müller S, et al. Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. Br J Haematol. 2018; 182(5): 735- 739. 5O'Suoji C, Welch JJ, Perkins SL, et al. Rare pediatric non-Hodgkin lymphomas: a report from Children's Oncology Group study ANHL 04B1. Pediatr Blood Cancer. 2016; 63(5): 794- 800. 6Ronceray L, Abla O, Barzilai-Birenboim S, et al. Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. Pediatr Blood Cancer. 2018; 65(4):e26932. 10.1002/pbc.26932 7Taddesse-Heath L, Pittaluga S, Sorbara L, Bussey M, Raffeld M, Jaffe ES. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol. 2003; 27(4): 522- 531. 8Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology. 2005; 128: 1579- 1605. 9Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012; 119(7): 1650- 1657. 10Quinti I, Agostini C, Tabolli S, et al. Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood. 2012; 120(9): 1953- 1954. 11Attarbaschi A, Carraro E, Abla O, et al. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. 2016; 101(12): 1581- 1591. 12Prunotto G, Offor UT, Samarasinghe S, et al. HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency. J Allergy Clin Immunol. 2020; 146(2): 447- 450. 13Piquer Gibert M, Alsina L, Giner Muñoz MT, et al. Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency. Eur J Pediatr. 2015; 174(8): 1069- 1076. 14Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017; 69(1): 35- 45. 15Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008; 87(4): 210- 219. 16Brito-Zerón P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017; 10(1): 90. 17Hernández-Molina G, Kostov B, Brito-Zerón P, et al. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology (Oxford). 2022; 62(1): 243- 255. 18Collado P, Kelada A, Cámara M, Zeft A, Flagg A. Extranodal marginal zone B cell lymphoma: an unexpected complication in children with Sjögren's syndrome. Reumatol Clin (Engl Ed). 2018; 14(4): 227- 229. 19Tesher MS, Esteban Y, Henderson TO, Villanueva G, Onel KB. Mucosal-associated lymphoid tissue (MALT) lymphoma in association with pediatric primary Sjogren syndrome: 2 cases and review. J Pediatr Hematol Oncol. 2019; 41(5): 413- 416. 20Fukumoto Y, Hosoi H, Kawakita A, et al. Sjögren's syndrome with MALT (mucosa-associated lymphoid tissue) lymphoma in a 13-year-old girl: a case report. Nihon Rinsho Meneki Gakkai Kaishi. 2000; 23(1): 49- 56. 21Basiaga ML, Stern SM, Mehta JJ, et al. Childhood Sjogren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria. Rheumatology (Oxford). 2021; 60(7): 3144- 3155. 22Ramos-Casals M, Acar-Denizli N, Vissink A, et al. Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology (Oxford). 2021; 60(10): 4558- 4567. 23Cimaz R, Casadei A, Rose C, et al. Primary Sjögren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003; 162(10): 661- 665. 24Wright TB. Updates in childhood Sjogren's syndrome. Curr Opin Pediatr. 2022; 34(2): 217- 222. 25Sandlund JT, Shurtleff SA, Onciu M, et al. Frequent mutations in SH2D1A (XLP) in males presenting with high-grade mature B-cell neoplasms. Pediatr Blood Cancer. 2013; 60(9): E85- E87. 26Alexander S, Aupérin A, Bomken S, et al. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: A prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Lancet Haematol. 2023: S2352-3026(23)00062-5. doi:10.1016/S2352-3026(23)00062-5 27Bomken S, van der Werff Ten Bosch J, Attarbaschi A, et al. Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group. Front Immunol. 2018; 9: 2912. doi:10.3389/fimmu.2018.02912. eCollection 2018. 28Bosch JVWT, Hlaváčková E, Derpoorter C, et al. How to recognize inborn errors of immunity in a child presenting with a malignancy: guidelines for the pediatric hemato-oncologist. Pediatr Hematol Oncol. 2023; 40(2): 131- 146. 29Attarbaschi A, Abla O, Arias Padilla L, et al. Rare non-Hodgkin lymphoma of childhood and adolescence: a consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. Pediatr Blood Cancer. 2020; 67(8):e2841630. 30Mellgren K, Attarbaschi A, Abla O, et al. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Ann Hematol. 2016; 95(8): 1295- 1305. Early ViewOnline Version of Record before inclusion in an issuee30476 ReferencesRelatedInformation